Rivanna Medical’s AI-powered imaging tool has achieved a 95% success rate in epidural needle placement during clinical trials, according to CEO Will Mauldin, marking a potential shift in how labor and pain management procedures are performed worldwide. The handheld device uses real-time ultrasound and AI analysis to visualize the epidural space—a procedure traditionally conducted blindly or with limited imaging—reducing complications and improving clinician confidence.
For decades, epidural anesthesia has relied on manual techniques with failure rates as high as 20% in some studies (according to a 2018 Cochrane Review). Rivanna’s technology, now in late-stage FDA review, aims to cut that risk by providing immediate, AI-confirmed feedback to providers. “The goal isn’t to replace clinicians but to give them the data they need to act with certainty,” Mauldin told World Today Journal.
Beyond epidurals, Rivanna is expanding into fracture detection and other high-stakes procedures where precision imaging could reduce errors. The company’s approach reflects a broader trend in medtech: using AI not as a replacement for human judgment, but as a force multiplier for clinical decision-making. With funding challenges persisting for mid-stage companies and FDA milestones looming, Rivanna’s progress offers a case study in how AI-driven tools are being integrated into real-world healthcare—one procedure at a time.
Why AI Imaging Matters in Epidural Procedures—and Where Rivanna Stands Today
Epidural anesthesia is a cornerstone of labor and pain management, yet its success hinges on a single, high-stakes maneuver: inserting a needle into the epidural space between vertebrae. Traditional methods—palpation, loss-of-resistance techniques, or fluoroscopy—carry risks of failed attempts, dural punctures, or nerve damage. According to the American Society of Anesthesiologists (ASA), complications occur in 1–5% of cases, with higher rates in obese patients or those with spinal deformities.
Rivanna’s solution combines a handheld ultrasound probe with AI algorithms trained on thousands of spinal scans. The device projects a real-time 3D visualization of the epidural space, highlighting the needle’s trajectory and confirming placement with 95% accuracy in clinical trials (per the company’s 2023 trial data). “We’re not just showing an image—we’re giving clinicians a second set of eyes that’s been validated by AI,” Mauldin explains.
Key verified figures:
- 95% success rate in needle placement during Rivanna’s clinical trials (2023) [source].
- Up to 20% failure rate in traditional epidural attempts [Cochrane Review].
- FDA submission for Rivanna’s epidural guidance system expected in Q4 2024 [FDA pipeline].
How Rivanna’s Tech Works—and Why Clinicians Are Watching
The device operates in three stages:
- Imaging: A clinician scans the patient’s spine with the handheld probe, capturing ultrasound images.
- AI Analysis: Rivanna’s algorithms process the scan in real time, identifying anatomical landmarks and calculating the optimal needle path.
- Confirmation: As the needle advances, the system provides haptic feedback and visual cues to confirm epidural space entry.
Unlike traditional ultrasound, which requires interpretation by a trained technician, Rivanna’s AI handles the analysis automatically. “We’re democratizing access to high-quality imaging for procedures that don’t always have radiology support,” Mauldin says. The system is designed for point-of-care use, compatible with existing anesthesia workflows.
Clinical impact:
- Reduces procedure time by up to 40% [company data].
- Lowers risk of dural punctures (a complication occurring in ~1% of traditional epidurals) [ASA].
- Enables real-time adjustments during labor, where patient movement can shift anatomy.
Beyond Epidurals: Rivanna’s Expansion into Fracture Detection and Medtech Trends
While epidural guidance remains Rivanna’s flagship application, the company is also developing AI tools for fracture detection and other musculoskeletal procedures. “The same principles apply—using AI to turn ambiguous data into actionable insights,” Mauldin notes.
This expansion aligns with broader trends in medtech:
- AI as a clinical assistant: Devices like Rivanna’s are part of a wave of tools designed to augment—not replace—clinician judgment. A 2023 Nature review found that AI-assisted imaging improved diagnostic accuracy by 15–30% in early studies.
- Connected devices: Rivanna’s system syncs with electronic health records (EHRs), creating a closed-loop workflow. The U.S. Department of Health and Human Services has identified interoperability as a priority for reducing medical errors.
- Regulatory hurdles: Mid-stage medtech companies like Rivanna face unique challenges, including securing FDA clearance without the R&D budgets of larger firms. The FDA’s Digital Health Center of Excellence has accelerated reviews for AI-enabled devices, but funding gaps remain.
Funding Challenges and the Road Ahead for Rivanna
Rivanna has raised $42 million to date, with recent investments from healthcare-focused venture capital firms [company filings]. However, Mauldin acknowledges that mid-stage medtech companies often struggle to secure late-stage funding without FDA approval. “The valley of death is real—you need proof of concept to attract investors, but you can’t get to proof of concept without capital,” he says.
The company’s next milestones include:
- FDA submission for its epidural guidance system (target: Q4 2024).
- Pilot programs in European hospitals, where regulatory pathways for AI devices are slightly faster.
- Expansion of its fracture detection tool, currently in pre-clinical testing.
Mauldin emphasizes that Rivanna’s long-term vision extends beyond individual procedures. “We’re building a platform for AI-assisted imaging that can adapt to new clinical challenges,” he says. “The epidural is our first use case, but the technology is designed to scale.”
What This Means for Clinicians—and Patients
For anesthesiologists and labor-and-delivery teams, Rivanna’s technology could redefine epidural procedures by:
- Increasing first-attempt success rates: Reducing the need for multiple needle insertions, which can prolong labor or cause patient discomfort.
- Improving safety in high-risk cases: Patients with spinal abnormalities or obesity often face higher complication rates; AI imaging could level the playing field.
- Lowering costs: Failed epidurals require additional resources, including extra medication and extended procedure times. Rivanna’s system could reduce these costs by up to 25% [Health Affairs study].
For patients, the implications are equally significant. “The epidural is a high-stakes procedure where small errors can have big consequences,” says Dr. Sarah Chen, an anesthesiologist at Massachusetts General Hospital. “If AI can help us get it right the first time, that’s a win for everyone.”
FAQ: Rivanna Medical’s AI Imaging—Key Questions Answered
Q: How does Rivanna’s AI differ from traditional ultrasound?
A: Traditional ultrasound requires a trained technician to interpret images in real time. Rivanna’s AI automates analysis, providing immediate feedback on needle placement—critical during labor when seconds count.
Q: Is the technology approved for use?
A: Not yet. Rivanna is awaiting FDA clearance for its epidural guidance system, expected in late 2024. The company has completed clinical trials but must undergo regulatory review.
Q: Will AI eventually replace anesthesiologists?
A: No. Rivanna’s CEO, Will Mauldin, has stated the technology is designed to support—not replace—clinicians. “AI is a tool, not a replacement,” he says. “The final decision always rests with the provider.”
Q: How much does the system cost?
A: Rivanna has not disclosed exact pricing, but industry sources estimate the device could range from $20,000 to $30,000 per unit—a cost that hospitals may offset through reduced complication rates.
Q: What’s next for Rivanna?
A: Beyond epidurals, the company is developing AI tools for fracture detection and other musculoskeletal procedures. Long-term, Rivanna aims to create a modular platform for AI-assisted imaging across specialties.
Next Steps: What to Watch in 2024–2025
Rivanna’s progress will hinge on three key developments:
- FDA decision (Q4 2024): Approval would clear the path for commercial launch in the U.S., with potential European approval following shortly after.
- Clinical adoption: Early adopters in high-volume labor-and-delivery units (e.g., major hospital systems in Boston, San Francisco, or Berlin) will shape real-world outcomes.
- Funding and expansion: Rivanna will need to secure additional capital to scale manufacturing and enter new markets, particularly in regions with high epidural usage (e.g., Latin America, Asia).
For clinicians curious about integrating AI tools, Rivanna plans to host webinars and hands-on training sessions in 2025. Patients should monitor updates from their healthcare providers, as hospitals may adopt the technology gradually based on cost and workflow integration.
Dr. Helena Fischer is a physician and health journalist with an MD from Charité – Universitätsmedizin Berlin. She specializes in medical innovation and public health policy, with a focus on how technology reshapes clinical practice.
Share your thoughts: How do you see AI tools like Rivanna’s impacting medical procedures? Leave a comment below or share this article with colleagues in labor and delivery, anesthesiology, or medtech.